当前位置: X-MOL 学术Lancet Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Neoadjuvant chemotherapy in oesophageal adenocarcinoma
The Lancet Oncology ( IF 51.1 ) Pub Date : 2017-11-01 , DOI: 10.1016/s1470-2045(17)30813-6
Lorenzo Fornaro , Giuseppe Aprile

Alderson and colleagues should be congratulated for the MRC OE05 trial,1 randomly assigning almost 900 patients with locally advanced, resectable oesophageal adenocarcinoma to cisplatin and fluorouracil (CF) for two cycles, or to epirubicin, cisplatin, and capecitabine (ECX) for four cycles, followed by surgery in both groups. The trial failed to demonstrate a significant overall survival improvement with ECX (hazard ratio 0·90, 95% CI 0·77–1·05; p=0·19).

中文翻译:

食管腺癌的新辅助化疗

应该对Alderson及其同事进行MRC OE05试验表示祝贺,1随机将近900例局部晚期可切除的食管腺癌患者分配为顺铂和氟尿嘧啶(CF)两个周期,或将表柔比星,顺铂和卡培他滨(ECX)分配为四个周期,然后两组均进行手术。该试验未能证明ECX能够显着改善总体生存率(危险比0·90,95%CI 0·77-1·05; p = 0·19)。
更新日期:2017-11-01
down
wechat
bug